Study wrapper · #976
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Garvey WT, Blüher M, Osorto Contreras CK, et al. The New England journal of medicine. 2025.
DOI: 10.1056/nejmoa2502081PubMed: 40544433
Editor's note
The pivotal REDEFINE 1 phase 3a trial (3417 participants, 68 weeks) reporting a mean weight change of -20.4% with cagrilintide-semaglutide versus -3.0% with placebo. Gastrointestinal adverse events were common but mostly mild-to-moderate and transient. High-quality primary human evidence directly on both tracked peptides.
Plain-language abstract
In this phase 3 trial, cagrilintide-semaglutide was associated with about 20% body-weight reduction versus 3% with placebo in adults with overweight or obesity.
Related coverage
Mixed
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
Lancet (London, England)n=——2026
Supported
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.
The lancet. Diabetes & endocrinologyn=——2026
Supported
Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
Lancet (London, England)n=——2026